The New England journal of medicine
-
Editorial Comment
Thrombolysis before Thrombectomy - To Be or DIRECT-MT?
-
Randomized Controlled Trial Multicenter Study
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear. ⋯ Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than among those who received placebo. (Funded by Merck Sharp & Dohme [a subsidiary of Merck] and Bayer; VICTORIA ClinicalTrials.gov number, NCT02861534.).